Background <p>Coronary CT angiography (CCTA) derived pericoronary fat attenuation index (FAI) is a reliable quantitative biomarker of vessel inflammation. However, whether this novel index mediated the relationship between metabolic dysfunction–associated fatty liver disease (MAFLD) and major adverse cardiovascular events (MACEs) remains unknown.</p> Methods <p>From January 2019 to December 2022, consecutive patients with stable chest pain who underwent CCTA and unenhanced abdominal CT were prospectively enrolled. All participants were divided into two groups-with MAFLD and without MAFLD according to abdominal CT results. The primary end point was MACEs, defined as cardiac death, nonfatal myocardial infarction, and late revascularization.</p> Results <p>A total of 135 participants with MAFLD and 232 without MAFLD were included in our study. The multivariate logistic regression analysis revealed that MAFLD was significantly associated with obstructive coronary artery disease (OR = 1.86, <i>p</i> = 0.024), high-risk plaque features ≥ 2 (adjusted OR = 2.34, <i>p</i> &lt; 0.001), CT derived fraction flow reserve ≤ 0.8 (adjusted OR = 1.88, <i>p</i> = 0.006), FAI ≥ -70.1HU (adjusted OR = 3.25, <i>p</i> &lt; 0.001) after adjusted for traditional risk factors. Participants with MAFLD showed a lower 36-month MACE-free survival rate than participants without MAFLD (54.0% vs. 83.5%, log-rank <i>p</i> &lt; 0.001). In addition, MAFLD was significantly associated with MACEs (HR = 3.65, 95%CI: 1.83, 7.26, <i>p</i> &lt; 0.001). Furthermore, mediation analysis revealed that FAI mediated 46.8% for the relationship between MAFLD and MACEs.</p> Conclusions <p>MAFLD is associated with CCTA derived plaque characteristics, including geometric, physiologic and inflammatory status. The relationship between MAFLD and MACEs might be partially mediated via coronary inflammation, which could be captured by FAI.</p> Clinical trial number <p>Not applicable.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Association of metabolic dysfunction–associated fatty liver disease with coronary CT angiography-derived plaque characteristics and cardiovascular events

  • Jin-jin Wang,
  • Xiao-lan Huang,
  • Yi Guo,
  • Xin-wei Tao,
  • Meng-su Zeng,
  • Yi-ding Ji,
  • Jian-jun Zhou,
  • Meng-meng Yu

摘要

Background

Coronary CT angiography (CCTA) derived pericoronary fat attenuation index (FAI) is a reliable quantitative biomarker of vessel inflammation. However, whether this novel index mediated the relationship between metabolic dysfunction–associated fatty liver disease (MAFLD) and major adverse cardiovascular events (MACEs) remains unknown.

Methods

From January 2019 to December 2022, consecutive patients with stable chest pain who underwent CCTA and unenhanced abdominal CT were prospectively enrolled. All participants were divided into two groups-with MAFLD and without MAFLD according to abdominal CT results. The primary end point was MACEs, defined as cardiac death, nonfatal myocardial infarction, and late revascularization.

Results

A total of 135 participants with MAFLD and 232 without MAFLD were included in our study. The multivariate logistic regression analysis revealed that MAFLD was significantly associated with obstructive coronary artery disease (OR = 1.86, p = 0.024), high-risk plaque features ≥ 2 (adjusted OR = 2.34, p < 0.001), CT derived fraction flow reserve ≤ 0.8 (adjusted OR = 1.88, p = 0.006), FAI ≥ -70.1HU (adjusted OR = 3.25, p < 0.001) after adjusted for traditional risk factors. Participants with MAFLD showed a lower 36-month MACE-free survival rate than participants without MAFLD (54.0% vs. 83.5%, log-rank p < 0.001). In addition, MAFLD was significantly associated with MACEs (HR = 3.65, 95%CI: 1.83, 7.26, p < 0.001). Furthermore, mediation analysis revealed that FAI mediated 46.8% for the relationship between MAFLD and MACEs.

Conclusions

MAFLD is associated with CCTA derived plaque characteristics, including geometric, physiologic and inflammatory status. The relationship between MAFLD and MACEs might be partially mediated via coronary inflammation, which could be captured by FAI.

Clinical trial number

Not applicable.